TRAW - Traws Pharma, Inc.

-

$undefined

N/A

(N/A)

Traws Pharma, Inc. NasdaqCM:TRAW Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Location: 12 Penns Trail, Newtown, PA, 18940, United States | Website: https://www.trawspharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-15.76M

Cash

21.34M

Avg Qtr Burn

-7.448M

Short % of Float

2.00%

Insider Ownership

19.68%

Institutional Own.

32.57%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rigosertib + Pembrolizumab Details
Melanoma, Skin cancer, Cancer

Phase 2

Data readout

Rigosertib Details
Cutaneous squamous cell carcinoma, Cancer, Solid tumor/s

Phase 2

Update

TRX100 (tivoxavir marboxil) Details
Influenza, Viral infection

Phase 2

Initiation

Phase 2a

Initiation

Rigosertib + Nivolumab Details
Cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

Narazaciclib + letrozole Details
Cancer, Solid tumor/s, Endometrial cancer

Phase 1/2

Data readout

Narazaciclib (ON 123300) Details
Solid tumor/s, Cancer, Breast cancer, ER+/HER2- breast cancer, Metastatic breast cancer

Phase 1/2

Update

Rigosertib Details
Myelodysplastic syndrome

Failed

Discontinued